These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23337757)

  • 1. Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.
    Madan RA; Gulley JL; Kantoff PW
    Cancer J; 2013; 19(1):50-8. PubMed ID: 23337757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in prostate cancer: review of the current evidence.
    Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
    Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for Prostate Cancer.
    Venturini NJ; Drake CG
    Cold Spring Harb Perspect Med; 2019 May; 9(5):. PubMed ID: 30201787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving role of immunotherapy in prostate cancer.
    Gerritsen WR
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
    Cheng ML; Fong L
    Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising immunotherapy for prostate cancer.
    Henegan JC; Sonpavde G
    Expert Opin Biol Ther; 2018 Feb; 18(2):109-120. PubMed ID: 29231062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
    Laccetti AL; Subudhi SK
    Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status of immunological approaches for the treatment of prostate cancer.
    Drake CG; Antonarakis ES
    Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in prostate cancer immunotherapies.
    Basler M; Groettrup M
    Drugs Aging; 2007; 24(3):197-221. PubMed ID: 17362049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
    Bilusic M; Heery C; Madan RA
    Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunotherapy for metastatic prostate cancer: do we really need this?].
    Heidenreich A
    Urologe A; 2012 Jan; 51(1):32-8. PubMed ID: 22258374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
    Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
    Antonarakis ES
    Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunotherapy for prostate cancer: recent developments and future challenges.
    Schweizer MT; Drake CG
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):641-55. PubMed ID: 24477411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in immunotherapy for the treatment of prostate cancer.
    Sonpavde G; Agarwal N; Choueiri TK; Kantoff PW
    Expert Opin Biol Ther; 2011 Aug; 11(8):997-1009. PubMed ID: 21675925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.